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Alström syndrome (ALMS) is a rare autosomal recessive multi-organ syndrome considered 
to date as a ciliopathy and caused by variations in ALMS1. Phenotypic variability is well-
documented, particularly for the systemic disease manifestations; however, early-onset 
progressive retinal degeneration affecting both cones and rods (cone-rod type) is universal, 
leading to blindness by the teenage years. Other features include cardiomyopathy, kidney 
dysfunction, sensorineural deafness, and childhood obesity associated with hyperinsulinemia 
and type 2 diabetes mellitus. Here, we present an unusual and delayed retinal dystrophy 
phenotype associated with ALMS in a 14-year-old female, with affected cone function 
and surprising complete preservation of rod function on serial electroretinograms (ERGs). 
High-throughput sequencing of the affected proband revealed compound heterozygosity 
with two novel nonsense variations in the ALMS1 gene, including one variant of de novo 
inheritance, an unusual finding in autosomal recessive diseases. To confirm the diagnosis 
in the context of an unusually mild phenotype and identification of novel variations, 
we  demonstrated the biallelic status of the compound heterozygous variations 
(c.[286C > T];[1211C > G], p.[(Gln96*)];[(Ser404*)]). This unique case extends our knowledge 
of the phenotypic variability and the pathogenic variation spectrum in ALMS patients.
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INTRODUCTION
Alström syndrome (ALMS; MIM 203800) is a rare autosomal recessive multi-organ disorder 
caused by homozygous or compound heterozygous predominantly truncating variations in the 
ALMS1 gene, with a prevalence of <1 case per 1,000,000 individuals (Collin et  al., 2002; Hearn 
et  al., 2002). The clinical presentation, largely overlapping with ciliopathies, is associated with 
retinal dystrophy, hearing loss, obesity, insulin resistance, type 2 diabetes, dilated cardiomyopathy, 
and progressive hepatic and renal dysfunction (Marshall et  al., 2005; Mockel et  al., 2011). 
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Retinal dystrophy of the cone-rod type is one of the earliest 
manifestations and presents with photophobia and nystagmus 
in early infancy (birth to 15  months; Aliferis et  al., 2012). It 
is characteristically rapidly progressive, with blindness by the 
teenage years. ALMS should be  suspected in children with 
obesity, retinal dystrophy, and dilated cardiomyopathy.
ALMS1 is composed of 23 exons and encodes a large protein 
of 4,169 amino acids, initially shown to localize to the centrosome 
and basal body (Hearn et  al., 2005; Knorz et  al., 2010) and also 
perturb actin filament organization (Zulato et al., 2011), suggesting 
a role in primary cilia function. Although mechanistic details 
are still lacking, ALMS1 is thought to be implicated in endosomal 
trafficking, actin organization, maintenance of centrosome cohesion, 
and transcription (for review, see Hearn, 2019). Clinical diagnosis 
of ALMS is often challenging in view of the heterogeneity of 
the clinical phenotype and overlapping features with other 
syndromes, in particular the Bardet-Biedl syndrome (BBS; MIM 
209900) with which it is often misdiagnosed (Aliferis et  al., 
2012). The retina often manifests disease first, misleading to a 
diagnosis of congenital achromatopsia, Leber Congenital Amaurosis, 
or isolated cone-rod dystrophy (Nasser et  al., 2018). More than 
230 pathogenic variations have been reported so far of which 
all are truncating variations (Marshall et  al., 2015; Astuti et  al., 
2017). We  report here the case of a 14-year-old female who 
presented with a very mild and unusual retinal phenotype 
displaying exclusive cone dystrophy with complete preservation 
of rod function on serial electroretinograms (ERGs), a 
cardiomyopathy, and a slight, bilateral, and symmetric hearing 
loss. Two novel class 4 variations (likely, pathogenic) according 
to the American College of Medical Genetics and Genomics 
(ACMG; Richards et  al., 2015) were identified within ALMS1. 
However, in view of the mild phenotype, the diagnosis was 
initially questioned. We, therefore, demonstrated that both ALMS1 
variations were in trans confirming the biallelic status of the 
variations. Interestingly, one of the variations occurred de novo. 
The diagnosis of ALMS with the following ALMS1 genotype 
was confirmed: c.[286C > T];[1211C > G], p.[(Gln96*)];[(Ser404*)].
CLINICAL REPORT
A 14-year-old girl born to non-consanguineous healthy 
French parents presented with central vision loss and 
photophobia at the age of 6. There were no symptoms of 
night blindness. Mild high frequency hearing loss was present, 
associated initially with recurrent otitis media. Past medical 
history revealed an episode of acute illness aged 1  month 
caused by hypokinetic cardiomyopathy. Her cardiac 
disease was stable aged 14 with residual left ventricular 
dilatation of a non-progressive nature and managed with 
5  mg/day of enalapril. Body mass index was normal with 
no endocrine abnormalities and a normal intellect 
(Supplementary Table  1).
Aged 14, visual acuity was limited to logMAR 0.60  in both 
eyes with no nystagmus. Low hyperopia associated with myopic 
astigmatism was present. Color vision was absent. Fundus 
examination revealed irregularity of the retinal pigment in 
the foveal region but normal peripheral retinal appearance, 
optic discs, and blood vessel caliber (Figures  1A–D). Ocular 
coherence tomography (OCT) scanning of the macula 
demonstrated irregularity of the ellipsoid zone, including the 
photoreceptors bilaterally (Figures 1E,F). Peripheral visual fields 
demonstrated mild loss of peripheral vision and loss of sensitivity 
in the central retina (Figure  2A).
ERG was first performed aged 7 and demonstrated cone 
dysfunction, with complete preservation of rod function. 
Repeated ERGs aged 9 and 13 confirmed absence of cone 
responses, with undetectable photopic ERG white flash 
responses and undetectable 30 Hz flicker responses. However, 
full dark-adapted rod responses were present, in keeping 
with an isolated cone dystrophy (Figure  2B). Although, the 
retinal phenotype was very unusual for ALMS, the diagnosis 
was considered because of the association of a retinal 
dystrophy with cardiomyopathy in infancy. Genetic analysis 
with family segregation was carried out to confirm 
the diagnosis.
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FIGURE 1 | Fundus photography, fundus autofluorescence, and optical coherence scanning images (OCT) of the patient’s retina. Fundus photography of right (A) 
and left (B) eyes demonstrates a granular appearance of the macula bilaterally (white arrows). No attenuation of retinal blood vessels can be observed. Fundus 
autofluorescence of right eye (C) and left eye (D) demonstrates increased autofluorescence of the fovea bilaterally (white arrows). OCT of right (E) and left (F) eye 
shows irregularity of the ellipsoid zone as well as an interdigitation zone in the macular region (white arrows).
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MATERIALS AND METHODS
Patient
The patient was referred for clinical investigations to the Alström 
National PHRC (“Programme Hospitalier pour la Recherche 
Clinique”) program held at the reference center for rare 
genetic eye disorders in the University Hospital of Strasbourg 
(CARGO, Centre de Référence pour les Affections Rares en 
Génétique Ophtalmologique). The study protocol had been 
approved by our Institutional Review Board “Comité Protection 
des Personnes” (EST IV, N°DC-20142222), and written informed 
consent was obtained. Our research complied with the Declaration 
of Helsinki. Best corrected visual acuity (BCVA) was assessed 
with a retroilluminated decimal Parinaud scale on a Luneau 
A
B
FIGURE 2 | Kinetic visual fields and electroretinogram (ERG) results. (A) Kinetic visual fields of the patient’s eyes shows marked central loss of sensitivity with some 
constriction of the peripheral visual field compared to the reference (control). (B) Full field ERG of both eyes were performed according to the ISCEV (International 
Society for clinical Electrophysiology of vision) standard. Undetectable full field cone ERGs (light adapted LA 3.0 and LA 30 Hz) with subnormal dark adapted (DA 0.01 
rod specific) and bright flash dark adapted (DA 10.0) compared to the reference (control is shown as small-integrated panels within each upper panels) is demonstrated.
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Charts Display L40. Semi-automated kinetic visual fields were 
performed with the Octopus 900 perimeter (Haag-Streit 
International, Wedel, Germany). Color vision was assessed with 
the Farnsworth Panel D-15 color vision cups and Ishihara 
plates. Slit lamp and dilated fundus examination were performed 
after pupillary dilatation with tropicamide 1%. Full-field ERG 
testing was performed with a modified version of the International 
Society for Clinical Electrophysiology of Vision (ISCEV) protocol 
under scotopic and photopic lighting conditions using Diagnosys 
LLC (Lowell, MA, US) device. Both spectral domain OCT and 
fundus autofluorescence images were acquired using the Spectralis 
HRA + OCT unit (Heidelberg Engineering, Heidelberg, Germany).
As well as ophthalmological assessment, the patient also 
underwent audiological and general physical examinations 
including height and weight with body mass index calculation, 
pure tone audiograms and review by an otologist, and renal 
and endocrine assessment by a general physician with 
measurement of serum urea and creatinine levels, renal 
echography, fasting glucose and HBA1C levels. Blood samples 
were obtained using standard venepuncture techniques after 
an overnight fast.
Targeted Exome Sequencing
High throughput sequencing of the patient’s sample was 
performed on the Ion Torrent PGM (Thermofisher) according 
to the manufacturer’s protocols. DNA libraries were constructed 
using the HaloPlex Target Enrichment system (Agilent 
Technologies, version D.5). The libraries were barcoded using 
HaloPlex ION Barcodes (Agilent Technologies) and then pooled 
by eight samples. Emulsion PCR was performed on the Ion 
One Touch 2 system (Life Technologies) and the emulsion 
PCR products enriched on the One Touch 2 Enrichment System 
using the Ion PGM Template OT2-200 kit (Life Technologies). 
Ion sphere particles (ISP) were enriched using the E/S module, 
charged on one Ion PGM 316 v2 chips and sequenced with 
an Ion Torrent PGM in a 200-bp configuration run. With an 
ISP loading of 55%, 149  Mb were produced in total out of 
1,264,061 reads, with a median length of 116  bp, of which 
12.3  Mb could be  used for our patient. Sequencing data were 
analyzed by the Torrent Suite Software v4.2.1 with alignment 
to the reference human genome (GRCh37/hg19) and base 
calling. Variant annotation and ranking were performed by 
VaRank (Geoffroy et  al., 2015) configured with the Alamut 
batch software (Interactive Biosoftware, Rouen, France). Filtering 
criteria were applied to identify the disease causing variations, 
including: (1) removing variants with an allele frequency >1% 
in public variation databases, such as the 1000 Genomes (The 
1000 Genomes Project Consortium et al., 2015) and the ExAC/
gnomAD databases (Lek et  al., 2016) or our internal patient 
database (350 samples); (2) removing variants in 5' and 3' 
UTR downstream and upstream locations, respectively and 
synonymous variations without pathogenic prediction of local 
splicing effect. The analysis was focused on compound 
heterozygous and homozygous variants consistent with a recessive 
mode of transmission. Each candidate variations were also 
checked using the Integrative Genomics Viewer (IGV) software 
(Thorvaldsdóttir et  al., 2012). The ALMS1 nomenclature is 
based on the RefSeq (O’Leary et  al., 2016) accession number 
NM_015120.4 and the identified variation.
DNA Analysis (PCR and Sequencing)
Sanger sequencing was performed using BigDye Terminator 
V1.1 Cycle Sequencing kit on an ABI3500 (Applied Biosystems, 
USA), according to the manufacturer’s instructions. Data were 
analyzed using SeqPilot (JSI Medical Systems, Germany; 
Figure  3). Primers are available in Supplementary Table  2.
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FIGURE 3 | Identification of two pathogenic variations in ALMS1. (A) Targeted exome sequencing reads aligned to exon 1 and 5 of the ALMS1 gene, displaying 
the two heterozygous variations in IGV (Thorvaldsdóttir et al., 2012). (B) Pedigree of the family together with Sanger sequencing of exon 1 and exon 5. A red star 
indicates the variation. The index case (II.1) harbors two nonsense variations in ALMS1, the c.286C > T (p.Gln96*) is inherited from the father (I.1) and the 
c.1211C > G (p.Ser404*) is de novo.
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Cells and RNA Extraction
Total RNA and proteins were obtained from dermal fibroblasts 
following skin biopsy. RNA was prepared from the cells using 
a RiboPure kit followed by a DNAse treatment with the TURBO 
DNA-free. Reverse transcription of 1  μg total RNA to cDNA 
was performed using the BioRad iScript™ cDNA Synthesis Kit 
(#170-8891, BioRad, USA).
RNA Quantification (RT-qPCR)
The qPCR reactions were prepared using the iQ SYBR Green 
Supermix (#170-8886, BioRad) according to the manufacturer’s 
instructions using 2  μl of cDNA. Reactions were set up in 
triplicate (three seperate controls and three separate DNA 
extractions for the patient). The cycling parameters were as 
follows: 95°C for 5  min, 45  cycles of 95°C for 15  s, and 60°C 
for 35  s, followed by the generation of melt curves by heating 
in 0.5°C increments (5 s/step) for the temperature range 65–95°C. 
Gene expression levels were quantified relative to the reference 
genes GAPDH and HPRT using the efficiency-corrected comparative 
cycle threshold (CT) method using the CFX Manager Software 
V.1.5 (BioRad). Primers are available in Supplementary Table 2.
RNA Sequencing
Three sets of primers (1F-6R for amplicon 1, Allele1F-6R for 
amplicon 2, and 1F-Allele5R for amplicon 3) were designed from 
a cDNA sequence according to the RefSeq identifier NM_015120.4 
using the Primer3 software1 (Figure 4; Supplementary Table 2). 
PCR reactions were carried out using 50  ng of cDNA, the Taq 
1 http://frodo.wi.mit.edu/primer3
A
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FIGURE 4 | Determining the biallelic status of the two variations using the patient’s RNA. (A) Schematic representation of the cDNA of ALMS1 with exon 
numbering and size shown. The regions targeted by each amplicon including two allele specific amplicons (Amplicon 2 and 3) together with a single control region 
(Amplicon 1). The primers targeting each variation are highlighted in blue and red (Supplementary Table 2). (B) Real-time quantitative polymerase chain reaction 
analysis from three technical replicates of II.1 and three controls fibroblasts showed a highly reduced relative expression levels of ALMS1 (normalized against 
GAPDH). (C) Electrophoresis gels and the corresponding sequences for the three amplicons are shown. Gels are labeled as following: L, Ladder; PT, Patient; WT, 
wild type control; and NTC, no template control. A single band in each gel and no band in the control for each allele specific (amplicon 2 and 3) demonstrate the 
specificity of the amplifications. When both variations are on distinct alleles as shown here, each sequence is normal with respect to the other variation.
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DNA polymerase (Sigma-Aldrich D4545-5KU), a PCR mix 5X 
containing a PCR Buffer 10× (100 mM tris-HCl, pH 8.3, 500 mM 
KCl), a solution of MgCl₂ (25 mM), and the four dNTP (200 μM). 
PCR conditions were as follow: denaturation at 95°C for 3  min 
followed by 35  cycles at 94°C for 30  s, 72°C for 30  s, and a 
final extension of 10  min at 72°C.
The PCR-amplified products underwent electrophoresis on 
a 1.5% agarose gel. The PCR fragments were purified using 
the AcroPrep™ 96 Filter Plate 350  μl (Pall Corporation) and 
sequencing performed by Eurofins Genomics using primers 
(5F, 4R, and 3R; Figure 4; Supplementary Table 2). Sequenced 
products were then compared with the ALMS1 transcript 
(NM_015120.4) using BioEdit® software and SeqScape Sofware 
(Applied Biosystems).
RESULTS
High throughout sequencing of a panel of 31 ciliopathy genes 
including ALMS1 (Redin et  al., 2012) revealed compound 
heterozygosity with the identification of two novel rare nonsense 
variations in the ALMS1 gene (Figure  3A). The two pathogenic 
variations include a C  >  T substitution at nucleotide 286  in 
exon 1, and a C  >  G substitution at nucleotide 1,211  in exon 
5, resulting, respectively in the replacement of glutamine at 
position 96 and serine at position 404 by premature stop codons 
(c.[286C  >  T(;)1211C  >  G]; p.[(Gln96*)(;)(Ser404*)]). Family 
co-segregation studies confirmed the paternal heritance of the 
c.286C  >  T (p.(Gln96*)) but no variation could be  observed in 
the mother’s DNA, suggesting that the c.1211C > G (p.(Ser404*)) 
was a de novo variation (Figure 3B). However, one cannot exclude 
a possible de novo occurrence on the paternal allele, especially 
in the context of an unusually mild phenotype. Thus, to confirm 
the potential consequences of the nonsense variants to the patient’s 
disease, we  showed a highly reduced level of ALMS1 RNA level 
(Figure 4B) and demonstrated the biallelic status of the variations 
using two allele-specific PCR reactions on the patient’s cDNA 
(Figure  4A), confirming that both ALMS1 pathogenic variants 
were indeed in trans (Figure  4C). Both variations have never 
been reported in previous studies (HGMD 2020.1; Stenson et al., 
2012), however the c.286C  >  T is listed in ClinVar under the 
following identifier RCV000672767.1 (Landrum et  al., 2018).
DISCUSSION
ALMS is a multisystemic autosomal recessive disorder associated 
with retinal dystrophy of the cone-rod type and severe early 
onset visual impairment (Marshall et  al., 2005; Nasser et  al., 
2018). Visual symptoms are often the first manifestation of the 
disease with nystagmus and photophobia in infancy or rarely in 
the pre-school years (Marshall et  al., 2005; Nasser et  al., 2018). 
Our proband presented with early-onset cardiomyopathy, associated 
with ALMS in 62% of cases, but normally accompanied or closely 
followed by the development of visual impairment and a cone-rod 
dystrophy, pointing toward the diagnosis (Marshall et  al., 2005). 
In this case, the late onset of visual symptoms, aged 6, was 
unusual as early-onset visual difficulties have been reported as 
universal in ALMS (Russell-Eggitt et  al., 1998; Marshall et  al., 
2005; Xu et  al., 2016; Nasser et  al., 2018). In the largest reported 
series of ALMS-related phenotypes (182 cases; Marshall et  al., 
2005), 98% of patients developed nystagmus and photophobia 
during the first year of life, with all patients in the series legally 
blind by the age of 15 (Marshall et al., 2005). However, variability 
in the severity of the ocular manifestations of ALMS has previously 
been described (Malm et  al., 2008; Nasser et  al., 2018). Malm 
and collaborators reported a patient with a mild ophthalmic 
phenotype who, aged 10, still had near-normal looking vessels 
and optic discs, diminished pigmentation of the fundus and visual 
fields with normal peripheral limits (Malm et al., 2008). However, 
in this mild case, both cone and rod function was mildly reduced 
upon ERG testing. A milder ophthalmic phenotype was also 
reported in a 26-year old female (Nasser et  al., 2018) diagnosed 
with achromatopsia in infancy due to the presence of nystagmus 
and photophobia at birth, who demonstrated residual vision 
(20/640 and 20/800, right and left eyes, respectively) in her 
mid-20s with visual field constriction in the left eye to 20–45 
degrees and a remaining crescent of paracentral visual field in 
the right eye (Nasser et al., 2018). Weiss et al. (2019) also reported 
a late presentation in a child presenting age 6 with nystagmus 
and impaired vision diagnosed with Leber Congenital Amaurosis. 
The child developed systemic features of ALMS (obesity, 
hypothyroidism, elevated transaminase levels, fatty liver, and 
acanthosis nigricans) in adolescence, confirming the importance 
of large-scale genotyping screening (Weiss et  al., 2019).
However, while variability in fundus appearance and retinal 
function assessed by serial ERGs has also been described 
(Tremblay et  al., 1993; Russell-Eggitt et  al., 1998; Van den 
Abeele et  al., 2001; Marshall et  al., 2005; Malm et  al., 2008), 
the presence of an exclusive cone dystrophy with complete 
preservation of rod function upon ERG testing in the early 
teenage years, as in our case, has, to our knowledge, not been 
previously reported.
The extent and progression of cone-rod dystrophy is an 
important prognostic feature for the quality of life of ALMS 
patients, and whilst the full-field ERG may be  quite similar 
to cone-rod dystrophies of other types, the progression of the 
retinal dystrophy in ALMS is usually very rapid (Russell-Eggitt 
et  al., 1998; Van den Abeele et  al., 2001), which has not been 
the case in our proband. Our case reinforces that the visual 
outcomes may vary considerably in ALMS.
In addition to the late presentation of first ophthalmic 
features aged 6, and presence of an exclusive cone dystrophy, 
our patient also had neither obesity nor insulin resistance/
diabetes type 2 (Marshall et  al., 2005). Childhood obesity is 
present in over 95% of individuals with ALMS with 
hyperinsulinemia in 92% of cases appearing in early childhood. 
Progression to type 2 diabetes mellitus has been reported in 
82% of those older than 16  years (Marshall et  al., 2005).
The classical association of ALMS with hypokinetic 
cardiomyopathy was present, occurring aged 1 month and resulting 
in stable left ventricular hypertrophy as a consequence. Fortunately, 
the episode proved non-progressive and without functional 
consequences, however, she remained on 5  mg of enalapril. 
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Hypokinetic cardiomyopathy is a well know feature of ALMS, 
with highly variable long-term clinical consequences (Makaryus 
et al., 2007). In a case series, dilated cardiomyopathy was reported 
in 62% of patients, with 43% of cases occurring in infancy (age 
1  week–16  months; Marshall et  al., 2005). In some patients, 
the infantile cardiomyopathy may be  reversible with treatment, 
but a risk of recurrence remains (Marshall et al., 2005; Makaryus 
et  al., 2007). Our patient also had mild bilateral sensorineural, 
predominantly high-frequency, hearing impairment evolving 
throughout childhood. Hearing loss is reported in 89% of patients 
with a mean age of onset of 5  years (Marshall et  al., 2005). 
Other atypical presentations of ALMS have been reported and 
include a case of putative isolated cardiomyopathy in a 2-month 
old child followed up until the age of 4.5  months (Nerakh and 
Ranganath, 2019). The infant did, however, develop significant 
weight gain (>95th centile; +3 SD) in the short follow up period 
(up to 4.5  months) and no formal visual assessments were 
conducted (Nerakh and Ranganath, 2019).
In this case, molecular analysis confirmed two novel compound 
heterozygous truncating variations in ALMS1. Compound 
heterozygosity and truncating variations are well described in 
ALMS, with many affected individuals displaying variations through 
exons 8 (25%), 10 (27%), and 16 (41%; Aliferis et al., 2012; Marshall 
et  al., 2013). The majority (96%) of the variations are nonsense 
or frameshift variations (insertions or deletions) leading to premature 
stop codons producing a truncated protein, or no protein at all 
(Marshall et  al., 2015; Astuti et  al., 2017; Chen et  al., 2017). 
We  highlight that nonsense-mediated decay (NMD) is likely to 
occur for our variants as both nonsense variants fall into the 
NMD-competent regions (NMD+) according to NMDEscPredictor 
(Coban-Akdemir et  al., 2018), a finding corroborated by the very 
low amount of RNA identified in the patient’s cells.
Given the mild phenotype, one could question whether, 
although unlikely, the second variation (c.1211C > G, p.Ser404*) 
that appeared de novo could have arisen on the same allele 
as the first variation. We thus worked on the patient’s fibroblasts 
and demonstrated the biallelic status of the two variations 
using allele-specific amplifications. To our knowledge, this is 
the first description of a de novo pathogenic variation in ALMS1. 
De novo variants contributing to autosomal recessive diseases 
are rare, as highlighted by large scale studies of whole exomes 
on more than 5,000 cases with developmental diseases. These 
studies did not report a single de novo variation contributing 
to a recessive condition, despite reporting more than 400 
autosomal recessive molecular diagnoses (Yang et  al., 2014; 
Retterer et  al., 2016). Black et  al. (2016) recommended the 
reporting of de novo variations in autosomal recessive disease, 
as he  uncovered two unrelated cases of an autosomal recessive 
disorder caused by the combination of one de novo and one 
inherited variant in a small series of nine families with severe 
fetal malformation (Black et al., 2016). According to the literature, 
the human de novo mutation rate ranges from 1.0 to 1.8 × 10−8 
per nucleotide per generation, leading to <90 de novo variants 
per genome among the 4–5 million variants identified by WGS 
(for review, see Acuna-Hidalgo et  al., 2016). The rate increases 
with paternal age, and 80% of de novo variants are of paternal 
origin. In our case however, the de novo nonsense variant 
occurred on the maternal allele and the mother’s age at 
conception was 32. The finding of a de novo variant contributing 
to ALMS in our proband has important implication for genetic 
counseling, since a clinical diagnosis of ALMS carries a reported 
recurrence risk of 25%. However, in this case because one of 
the causative variants arose de novo, the recurrence risk is 
markedly reduced, with significant implications for future 
reproductive decisions. A small finite risk remains, however, 
owing to the possibility of germ-line mosaicism in the father/
mother. Recurrence risks given by clinical geneticists in such 
cases are generally stated around 1%. However, one must remain 
cautious as depending on the gene or disease, parental germline 
mosaicism levels may be  much higher ranging from 5% to as 
high as 15% (Veltman and Brunner, 2012; Myers et  al., 2018).
Our analyses confirmed the biallelic status of the variations 
in the context of a mild phenotype. To date, contributing 
factors to phenotypic variability in ALMS remain largely 
unexplored and may include the presence of modifier alleles 
and the influence of epigenetic and/or environmental factors. 
The lifespan of patients with ALMS may not exceed 40  years 
(Aliferis et al., 2012), however early diagnosis and intervention 
can moderate the progression of some of the disease phenotypes 
and improve longevity and quality of life for patients.
CONCLUSION
In this unusual presentation of ALMS, we  identified two novel 
pathogenic variations in ALMS1 that contribute to the high 
variation load within this gene. This specific case highlights 
both the genetic and phenotypic variability in ALMS, with an 
unusually mild retinal dystrophy of the exclusive cone type, 
a mild cardiac phenotype with absence of endocrine 
abnormalities, and the presence of a de novo variation, a 
potentially largely overlooked finding in recessive diseases.
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